Biopsy-Based Transcriptomics of Banff 2022 Antibody-Mediated Rejection Categories
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F25%3A00085796" target="_blank" >RIV/00023001:_____/25:00085796 - isvavai.cz</a>
Result on the web
—
DOI - Digital Object Identifier
—
Alternative languages
Result language
angličtina
Original language name
Biopsy-Based Transcriptomics of Banff 2022 Antibody-Mediated Rejection Categories
Original language description
A recent Banff 2022 update reclassified antibody-mediated rejection (AMR)based on the presence of microvascular inflammation (MVI), C4d positivity, and donor-specificantibodies (DSA). The role of molecular assessment in biopsies with active and/or chronic AMRfeatures remains unexplored.
Czech name
—
Czech description
—
Classification
Type
O - Miscellaneous
CEP classification
—
OECD FORD branch
30213 - Transplantation
Result continuities
Project
<a href="/en/project/LX22NPO5104" target="_blank" >LX22NPO5104: National Institute for Research of Metabolic and Cardiovascular Diseases</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2025
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů